Katrina A Morris

Learn More
Antibodies to native glycosylated myelin oligoden-drocyte glycoprotein (MOG), measured by cell-based assays, have been reported in adults with acute disseminated encephalomyelitis (ADEM) and in children with demyelinating diseases, including multiple sclerosis (MS) and ADEM. More recently, antibodies to both truncated 1 and full-length 2 MOG have been(More)
Earlier research has shown that cutaneous experimental pain can elevate the vibrotactile threshold at the same skin locus. The purpose of this study was to determine whether vibrotactile and pain thresholds in a clinical (temporomandibular disorders [TMD]) population are consistent with the hypothesis that chronic pain causes a similar elevation.(More)
OBJECTIVE To compare the sensitivity of linear and volumetric measurements on MRI in detecting schwannoma progression in patients with neurofibromatosis type 2 on bevacizumab treatment as well as the extent to which this depends on the size of the tumour. METHODS We compared retrospectively, changes in linear tumour dimensions at a range of thresholds to(More)
OBJECTIVE People with neurofibromatosis Type 2 (NF2) have a genetic predisposition to nervous system tumors. NF2-associated schwannomas stabilize or decrease in size in over half of the patients while they are receiving bevacizumab. NF2 patients treated with bevacizumab for rapidly growing schwannoma were retrospectively reviewed with regard to ependymoma(More)
Bevacizumab is considered an established part of the treatment strategies available for schwannomas in patients with Neurofibromatosis type 2 (NF2). In the UK, it is available through NHS National Specialized Commissioning to NF2 patients with a rapidly growing target schwannoma. Regrowth of the tumour on suspension of treatment is often observed resulting(More)